Details
| Stereochemistry | ABSOLUTE |
| Molecular Formula | C10H12F3N |
| Molecular Weight | 203.2042 |
| Optical Activity | ( + ) |
| Defined Stereocenters | 1 / 1 |
| E/Z Centers | 0 |
| Charge | 0 |
SHOW SMILES / InChI
SMILES
C[C@H](N)CC1=CC=CC(=C1)C(F)(F)F
InChI
InChIKey=MLBHFBKZUPLWBD-ZETCQYMHSA-N
InChI=1S/C10H12F3N/c1-7(14)5-8-3-2-4-9(6-8)10(11,12)13/h2-4,6-7H,5,14H2,1H3/t7-/m0/s1
| Molecular Formula | C10H12F3N |
| Molecular Weight | 203.2042 |
| Charge | 0 |
| Count |
|
| Stereochemistry | ABSOLUTE |
| Additional Stereochemistry | No |
| Defined Stereocenters | 1 / 1 |
| E/Z Centers | 0 |
| Optical Activity | UNSPECIFIED |
Approval Year
| Substance Class |
Chemical
Created
by
admin
on
Edited
Tue Apr 01 16:28:50 GMT 2025
by
admin
on
Tue Apr 01 16:28:50 GMT 2025
|
| Record UNII |
CLX07A6ZIY
|
| Record Status |
Validated (UNII)
|
| Record Version |
|
-
Download
| Name | Type | Language | ||
|---|---|---|---|---|
|
Preferred Name | English | ||
|
Common Name | English | ||
|
Systematic Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Systematic Name | English | ||
|
Systematic Name | English | ||
|
Common Name | English | ||
|
Common Name | English |
| Code System | Code | Type | Description | ||
|---|---|---|---|---|---|
|
9815618
Created by
admin on Tue Apr 01 16:28:50 GMT 2025 , Edited by admin on Tue Apr 01 16:28:50 GMT 2025
|
PRIMARY | |||
|
19036-73-8
Created by
admin on Tue Apr 01 16:28:50 GMT 2025 , Edited by admin on Tue Apr 01 16:28:50 GMT 2025
|
PRIMARY | |||
|
CLX07A6ZIY
Created by
admin on Tue Apr 01 16:28:50 GMT 2025 , Edited by admin on Tue Apr 01 16:28:50 GMT 2025
|
PRIMARY | |||
|
242-769-7
Created by
admin on Tue Apr 01 16:28:50 GMT 2025 , Edited by admin on Tue Apr 01 16:28:50 GMT 2025
|
PRIMARY | |||
|
DTXSID30862774
Created by
admin on Tue Apr 01 16:28:50 GMT 2025 , Edited by admin on Tue Apr 01 16:28:50 GMT 2025
|
PRIMARY |
| Related Record | Type | Details | ||
|---|---|---|---|---|
|
|
RACEMATE -> ENANTIOMER |
|
||
|
|
OFF-TARGET->AGONIST |
Responsible for valvular heart disease (VHD) with the administration of phentermine and fenfluramine (phen/fen) and dexfenfluramine1 led to the withdrawal of fenfluramine and dexfenfluramine from the marketplace in September 1997.
Ki
|
||
|
TARGET -> AGONIST |
Ki
|
||
|
|
SALT/SOLVATE -> PARENT |
|
| Related Record | Type | Details | ||
|---|---|---|---|---|
|
|
PARENT -> METABOLITE TOXIC |
DF itself binds only weakly to the 5-HT2A, 5-HT2B, and 5-HT2C receptors, its primary metabolite, N-des-ethyl-DF (norDF, Figure 2), is a high-affinity 5-HT2B ligand with selectivity relative to 5-HT2A and 5-HT2C (5-HT2B Ki = 11.2 ± 4.3 nM). May be responsible for valvular heart disease (VHD).
|
